Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

SOP for Out of Specification (OOS) Handling in Transdermal Patches Production

Posted on By

SOP for Out of Specification (OOS) Handling in Transdermal Patches Production

Standard Operating Procedure for Out of Specification (OOS) Handling in Transdermal Patches Production

1) Purpose

The purpose of this SOP is to establish a standardized procedure for the identification, investigation, and resolution of out-of-specification (OOS) results in the production and quality control of transdermal patches, ensuring compliance with regulatory requirements and maintaining product quality.

2) Scope

This SOP applies to all personnel involved in the production, quality control, and quality assurance of transdermal patches, as well as any other departments that may encounter OOS results during their activities.

3) Responsibilities

The Quality Assurance (QA) Department is responsible for overseeing the OOS handling process. All personnel are responsible for identifying, reporting, and investigating OOS results and cooperating in the resolution process.

4) Procedure

4.1 Identification and Reporting of OOS Results

  • 4.1.1 Identify any test results that fall outside the established specifications or acceptance criteria during production or quality control testing.
  • 4.1.2 Immediately report the OOS result to the supervisor and the QA Department using the OOS Report Form.
  • 4.1.3 Document the details of the OOS result, including date, time, test method, and any immediate corrective actions taken, in the OOS Report Form.
See also  SOP for Compatibility Testing of Transdermal Patches with Packaging Materials

4.2 Initial Laboratory Investigation

  • 4.2.1 The QC Department conducts an initial laboratory
investigation to confirm the OOS result and identify any potential analytical errors or discrepancies.
  • 4.2.2 Review the test method, equipment calibration, reagent quality, and analyst technique to determine if any errors occurred during testing.
  • 4.2.3 Repeat the test using the same sample if an analytical error is suspected. Document all findings and actions in the OOS Report Form.
  • 4.3 Full-Scale OOS Investigation

    • 4.3.1 If the initial laboratory investigation does not identify an analytical error, initiate a full-scale OOS investigation involving a cross-functional team, including representatives from QA, Production, and QC.
    • 4.3.2 Conduct a comprehensive review of the batch records, raw material quality, production process, and environmental conditions to identify potential causes of the OOS result.
    • 4.3.3 Collect additional samples, if necessary, to perform retesting or further analysis. Document all investigation activities and findings in the OOS Investigation Report.

    4.4 Root Cause Analysis and CAPA

    • 4.4.1 Perform a root cause analysis to identify the underlying cause(s) of the OOS result, considering all potential factors from raw materials to finished product testing.
    • 4.4.2 Develop and implement corrective actions to address the immediate cause of the OOS result and prevent recurrence.
    • 4.4.3 Identify and implement preventive actions to eliminate the root cause and prevent similar OOS results in the future. Document all CAPA activities in the OOS Investigation Report.

    4.5 Review and Approval

    • 4.5.1 The QA Department reviews the completed OOS Investigation Report, including CAPA activities, to ensure adequacy and completeness.
    • 4.5.2 Obtain final approval from the QA Manager or designee before closing the OOS report and releasing the batch for further processing or distribution.

    4.6 Documentation and Trending

    • 4.6.1 Maintain all OOS reports and related documentation in a centralized OOS Log.
    • 4.6.2 Conduct periodic reviews and trend analysis of OOS results to identify patterns or areas for process improvement.
    • 4.6.3 Implement process improvements based on trending analysis to enhance product quality and compliance.

    5) Abbreviations, if any

    SOP: Standard Operating Procedure
    QA: Quality Assurance
    QC: Quality Control
    OOS: Out of Specification
    CAPA: Corrective and Preventive Actions

    6) Documents, if any

    OOS Report Form
    OOS Investigation Report
    OOS Log
    Batch Records
    CAPA Documentation

    7) Reference, if any

    ICH Q10: Pharmaceutical Quality System
    21 CFR Part 211: Current Good Manufacturing Practice for Finished Pharmaceuticals
    FDA Guidance for Industry: Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production

    8) SOP Version

    Version 1.0

    See also  SOP for Continuous Improvement in Transdermal Patches Production
    Transdermal Patches Tags:Adhesion Testing Protocol, Analytical Method Development SOP, Assay of Active Ingredient SOP, Contamination Prevention SOP, Documentation SOP, Equipment calibration SOP, Equipment Cleaning SOP, Final Product Inspection SOP, Formulation development SOP, Homogeneity Testing SOP, In-process Testing SOP, Microbial Testing SOP, Personnel Training SOP, Process Optimization SOP, Process Validation SOP, Quality Control Transdermal Patches, Raw Material Inspection SOP, Release Rate Testing SOP, Sample Collection SOP, Sterility Maintenance SOP, Storage Conditions Transdermal Patches, Thickness Testing Procedure, Transdermal Patch Manufacturing SOP, Transdermal Patch Stability Testing, Waste Handling SOP

    Post navigation

    Previous Post: SOP for Deviation Handling in Transdermal Patches Production
    Next Post: SOP for Pharmacovigilance Crisis Management

    Standard Operating Procedures V 1.0

    • Aerosols
    • Analytical Method Development
    • Bioequivalence Bioavailability Study
    • Capsule Formulation
    • Clinical Studies
    • Creams
    • Data Integrity
    • Dental Dosage Forms
    • Drug Discovery
    • Environment, Health and Safety
    • Formulation Development
    • Gels
    • Good Distribution Practice
    • Good Warehousing Practices
    • In-Process Control
    • Injectables
    • Liquid Orals
    • Liposome and Emulsion Formulations
    • Lotions
    • Lyophilized Products
    • Maintenance Dept.
    • Medical Devices
    • Metered-Dose Inhaler
    • Microbiology Testing
    • Nanoparticle Formulation
    • Nasal Spray Formulations
    • Nebulizers
    • Ocular (Eye) Dosage Forms
    • Ointments
    • Otic (Ear) Dosage Forms
    • Pharmacovigilance
    • Powder & Granules
    • Purchase Departments
    • Quality Assurance
    • Quality Control
    • Raw Material Stores
    • Regulatory Affairs
    • Tablet Manufacturing
    • Rectal Dosage Forms
    • Transdermal Patches
    • Vaginal Dosage Forms
    • Validations and Qualifications

    Read SOPs in your Language:

     - 
    Bengali
     - 
    bn
    English
     - 
    en
    Gujarati
     - 
    gu
    Hindi
     - 
    hi
    Malayalam
     - 
    ml
    Marathi
     - 
    mr
    Punjabi
     - 
    pa
    Tamil
     - 
    ta
    Telugu
     - 
    te

    NEW! Revised SOPs – V 2.0

    • Aerosols V 2.0
    • Analytical Method Development V 2.0
    • API Manufacturing V 2.0
    • BA-BE Studies V 2.0
    • Biosimilars V 2.0
    • Capsules V 2.0
    • Creams V 2.0
    • Elixers V 2.0
    • Ointments V 2.0
    • Raw Material Warehouse V 2.0
    • Tablet Manufacturing V2.0

    New Publication: A must for All.

    Copyright © 2025 SOP Guide for Pharma.

    Powered by PressBook WordPress theme

    Go to mobile version